BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Bionor Pharma ASA 

6701 Democracy Boulevard
Suite 300
Bethesda  Maryland  20817  U.S.A.
Phone: 301-571-9493 Fax: 301-564-9619


SEARCH JOBS




Industry
Biotechnology






 Company News
Bionor Pharma ASA's Phase II Vacc-4x Data Published In The Lancet Infectious Diseases 2/11/2014 9:32:10 AM
Bionor Pharma ASA Appoints Anker Lundemose New VP and CEO 1/29/2013 7:02:25 AM
Bionor Pharma ASA Release: Final Regulatory Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial 12/5/2012 9:37:03 AM
Bionor Pharma ASA Release: Analysis of Immune Responses in Patients Treated With Vacc-4x Supports Further Development 9/12/2012 10:05:37 AM
Bionor Pharma ASA Release: Study of Vacc-4x Combined With Celgene (CELG)'s Revlimid® (lenalidomide) in HIV Patients With Impaired Immune System Approved to Begin 8/13/2012 8:48:18 AM
Bionor Pharma ASA's Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load and Potential for Periodic "Boosts" That Could Result in New Treatment Option for People Living With HIV/AIDS 7/20/2012 9:18:04 AM
HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma ASA 7/17/2012 9:12:52 AM
GLOBVAC Awards Bionor Pharma ASA US $1.7 Million to Advance Research Towards an HIV Cure Using Vaccine Vacc-4x 7/9/2012 8:56:57 AM
Bionor Pharma ASA Release: International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5 6/7/2012 9:01:03 AM
Bionor Pharma ASA Release: International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus 6/7/2012 8:58:30 AM
123